ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 28 of 139 for:    "Measles"

Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR (BREMEAVAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02325310
Recruitment Status : Completed
First Posted : December 24, 2014
Last Update Posted : May 1, 2018
Sponsor:
Collaborators:
Service de Bactériologie-Virologie-Hygiène, CHU Limoge
GO-CIC network (Réseau Gynéco-Obstetrical des Centres d’Investigation Clinique)
REIVAC network (Réseau National d’Investigation Clinique en Vaccinologie)
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
In order to assess the safety of breastfed infants after their mother's postpartum immunization with a combined measles-mumps-rubella (MMR) vaccine, the purpose of this study is to investigate whether measles vaccine strain is excreted in breast milk of breastfeeding women with negative rubella and measles serologies.

Condition or disease Intervention/treatment Phase
Measles Rubella Mumps Biological: Combined measles-mumps-rubella (MMR) vaccine - PRIORIX® Phase 4

Detailed Description:

This is a multicentre prospective study, to evaluate the safety of infant from 50 breastfeeding women, analyzable for primary endpoint, after postpartum immunization with MMR vaccine.

During the screening period, eligibility will be determined based on the inclusion and exclusion criteria. Medical records of pregnant women will be screened by study investigators, who will then propose to the woman to participate to the study during a phone call or a follow-up visit. Screening visit could take place 4 months before delivery planned date up until the day of delivery.

The investigator will explain the study to the woman. A copy of the informed consent documents will be given to the woman for reading and for further information about the study (by email, by post, or personally).

If the woman is willing to participate to the study and after she had given her screening informed consent, a blood sample for measles serological analysis will be drawn.

After signing the consent, women meeting all the inclusion criteria and none of the exclusion criteria will be vaccinated in post partum and before the exit of the maternity at day 0.

Each woman will have a blood draw at day 0 and breast milk samples as well as urine samples at the hospital at day 0 before vaccination.

Each included woman will also provide breast milk and urine home samples at days 7, 11 and 14 after vaccination. Reminder calls will be performed at days 7, 11 and 14 after vaccination.

Women will then be followed and vaccinated 8 weeks after the first vaccination, visit V1.

Each infant will be followed during 8 weeks. An optional blood sample for immunological analysis will be drawn at week 8 (visit v1). Informed consent form signed by the person(s) holding parental authority (both parents or mother only if the father has no parental authority) is needed for the infant to be included as well.

Diary cards will be used to follow the infant and the mother. If Infant and/or mother develop(s) suspected measles symptom(s), they will be evaluated by a study physician as soon as possible, preferably within 24 to 72 hours of acute measles symptom(s) onset.

In case of mother symptoms, infant will be also seen by a physician during mother's supplementary visit.

The visit at day 0 (V0) of the study will be performed at the maternity. The other visits, screening visit, V1 and supplementary visit (SV), will be performed either at the maternity or at the corresponding CIC if applicable. Home samples at 7, 11 and 14 days after vaccination will be directly sent at the laboratory of virology at Limoges. Home sampling can also be performed at the maternity or CIC according to their internal organization.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine
Actual Study Start Date : February 4, 2015
Actual Primary Completion Date : May 3, 2016
Actual Study Completion Date : November 1, 2017


Arm Intervention/treatment
Experimental: Breastfeeding women
70 breastfeeding women meeting all the inclusion criteria and none of the exclusion criteria will be immunized with MMR vaccine in postpartum (before the exit of the maternity)
Biological: Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®
One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.




Primary Outcome Measures :
  1. Prevalence of the measles vaccine virus strain in breast milk. [ Time Frame: day 7 after the first vaccination. ]
    Number of women with positive RT-PCR for measles vaccine virus strain in breast milk for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction

  2. Prevalence of the measles vaccine virus strain in breast milk. [ Time Frame: day 11 after the first vaccination. ]
    Number of women with positive RT-PCR for measles vaccine virus strain in breast milk for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction

  3. Prevalence of the measles vaccine virus strain in breast milk. [ Time Frame: day 14 after the first vaccination. ]
    Number of women with positive RT-PCR for measles vaccine virus strain in breast milk for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction


Secondary Outcome Measures :
  1. Number of infants with reported clinical symptoms of measles [ Time Frame: At V1 Visit (8 weeks +/- 15 days) ]
    Evaluation of the clinical impact of MMR vaccination in breastfeeding infant

  2. Number of infants with reported clinical symptoms of measles [ Time Frame: Between V0 visit and V1 visit (8 weeks +/- 15 days) after the first MMR vaccination ]
    Evaluation of the clinical impact of MMR vaccination in breastfeeding infant from data reported in the infant diary card (DiCa).

  3. Number of women with reported clinical symptoms of measles [ Time Frame: V1 Visit (8 weeks +/- 15 days) after the first MMR vaccination ]
    Evaluation of the clinical impact of MMR vaccination in breastfeeding infant from mother clinical data

  4. Number of women with reported clinical symptoms of measles [ Time Frame: Between V0 visit and V1 visit (8 weeks +/- 15 days) after the first MMR vaccination ]
    Evaluation of the clinical impact of MMR vaccination in breastfeeding infant from mother clinical data repoted in the diary card (DiCa).

  5. Number of infants with positive measles serology (IgM) [ Time Frame: V1 visit (8 weeks +/- 15 days) after the first MMR vaccination ]
    Evaluation of the immunological impact of MMR vaccination in breastfeeding infant.

  6. Number of women with positive RT-PCR for measles vaccine virus strain in urine in at least one sample [ Time Frame: At day 7 after the first vaccination. ]
    For detection of measles vaccine strain excretion in urine of breastfeeding women, the number of women, with negative rubella and measles serologies with positive RT-PCR for measles vaccine virus strain in urine for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine will be assessed. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction

  7. Number of women with positive RT-PCR for measles vaccine virus strain in urine in at least one sample [ Time Frame: At day 11 after the first vaccination. ]
    For detection of measles vaccine strain excretion in urine of breastfeeding women, the number of women, with negative rubella and measles serologies with positive RT-PCR for measles vaccine virus strain in urine for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine will be assessed. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction

  8. Number of women with positive RT-PCR for measles vaccine virus strain in urine in at least one sample [ Time Frame: At day 14 after the first vaccination. ]
    For detection of measles vaccine strain excretion in urine of breastfeeding women, the number of women, with negative rubella and measles serologies with positive RT-PCR for measles vaccine virus strain in urine for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine will be assessed. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction

  9. Quantification of the measles vaccine virus strain presented in breast milk in at least one sample [ Time Frame: At day 7 after the first vaccination. ]
    In case of detection of measles vaccine virus strain excretion in breast milk, RT-PCR quantification measure of measles vaccine virus strain in woman breastmilk will be performed.

  10. Quantification of the measles vaccine virus strain presented in breast milk in at least one sample [ Time Frame: At day 11 after the first vaccination. ]
    In case of detection of measles vaccine virus strain excretion in breast milk, RT-PCR quantification measure of measles vaccine virus strain in woman breastmilk will be performed.

  11. Quantification of the measles vaccine virus strain presented in breast milk in at least one sample [ Time Frame: At day 14 after the first vaccination. ]
    In case of detection of measles vaccine virus strain excretion in breast milk, RT-PCR quantification measure of measles vaccine virus strain in woman breastmilk will be performed.

  12. Microscopy assessment of the infectious activity of the measles vaccine virus presented in breast milk in at least one sample. [ Time Frame: At day 7 ]
    In case of detection of measles vaccine virus strain excretion in breast milk. The evaluation of the infectious activity of the measles vaccine virus will be performed using an in vitro infectivity assay. A result will be considered as positive when at least one positive fluorescent cell is detected.

  13. Microscopy assessment of the infectious activity of the measles vaccine virus presented in breast milk in at least one sample. [ Time Frame: At day 11 after the first vaccination. ]
    In case of detection of measles vaccine virus strain excretion in breast milk. The evaluation of the infectious activity of the measles vaccine virus will be performed using an in vitro infectivity assay. A result will be considered as positive when at least one positive fluorescent cell is detected.

  14. Microscopy assessment of the infectious activity of the measles vaccine virus presented in breast milk in at least one sample. [ Time Frame: At day 14 after the first vaccination. ]
    In case of detection of measles vaccine virus strain excretion in breast milk. The evaluation of the infectious activity of the measles vaccine virus will be performed using an in vitro infectivity assay. A result will be considered as positive when at least one positive fluorescent cell is detected.

  15. Number of infant with positive salivary IgM/IgG [ Time Frame: one year after the first vaccination ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 36 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Women:

  • Pregnant woman
  • Age ≥ 18 years
  • Planning to breastfeed her infant (mixed feeding is allowed)
  • Having a negative serology for rubella during pregnancy
  • Negative serology for measles based on the result from local laboratory
  • Affiliated to a social security regimen

Infants:

  • Informed consent form signed by the person(s) holding parental authority.
  • Term newborn (≥36LMP)

Exclusion Criteria:

Women:

  • Woman having a multiple pregnancy
  • Woman planning to get pregnant in the month following the 2nd vaccination
  • Woman with known or suspected HIV infection
  • Woman with known or suspected immunodeficiency
  • Woman with family history of hereditary immune deficiency
  • Woman not mastering enough the reading / understanding of the French language to be able to consent to participate to the study
  • Woman incapable to follow the procedures of the study and to respect study visits for the whole period of the study.
  • Woman with contraindication for MMR vaccination:

    • Scarce hereditary problems of fructose intolerance
    • Woman with history of hypersensitivity to the active substances or to any of the excipients of the vaccine
    • Administration of human gammaglobulins in the past 3 to 11 months depending on the dose of human globulins administered (except for Rhophylac®)
    • Acute severe febrile illness within 7 days prior to injection
  • Woman under systemic corticosteroids (prednisone, or equivalent ≥10 mg/day) within the previous 15 days or planning to use corticosteroids (i.e. prednisone, or equivalent ≥10 mg/day) during the 15 days following vaccination
  • Woman under immunosuppressive therapy within the previous 3 months before vaccination or planning to use immunosuppressive therapy during the 15 days following vaccination Woman participating in any clinical trial with another investigational product 28 days prior to visit V0 or intent to participate in another clinical study with another investigational product at any time during the conduct of this study
  • Any other reason which, according to the investigator, may interfere with the evaluation of the study objectives
  • Woman with documented history of measles vaccination (1 or 2 doses) and/or history of documented measles

Infants:

  • Blood draw is contraindicated or cannot be performed
  • Infant with family history of hereditary immune deficiency
  • Infant with suspected or confirmed immunodeficiency
  • Any other reason which, according to the investigator, may interfere with the evaluation of the study objectives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02325310


Locations
France
Cochin Port Royal Hospital - Centre d'Investigation Clinique Cochin-Pasteur
Paris, France, 75014
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Service de Bactériologie-Virologie-Hygiène, CHU Limoge
GO-CIC network (Réseau Gynéco-Obstetrical des Centres d’Investigation Clinique)
REIVAC network (Réseau National d’Investigation Clinique en Vaccinologie)
Investigators
Study Director: Odile Launay, MD, PhD Assistance Publique - Hôpitaux de Paris

Additional Information:
Publications:
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02325310     History of Changes
Other Study ID Numbers: 2014-001538-28
First Posted: December 24, 2014    Key Record Dates
Last Update Posted: May 1, 2018
Last Verified: April 2018

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Vaccine strain excretion in breast milk
Postpartum vaccination
Breastfeeding women
Measles-mumps-rubella vaccine
Breast milk
Vaccinology

Additional relevant MeSH terms:
Measles
Rubella
Morbillivirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases
Rubivirus Infections
Togaviridae Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs